Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) and partner Sandoz have created a generic version of the drug which is awaiting approval from the U.S. Food and Drug Administration. Drug company Mylan also has plans to market a generic version of the drug.Momenta (Nasdaq: MNTA) CFO Rick Shea said in an interview today that the other eight patents all expire on May 24. He said the FDA could … Continue reading Bullish Stocks: Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), Kindred Healthcare, Inc. (NYSE:KND), Ur-Energy (NYSEMKT:URG), Bonanza Creek Energy Inc (NYSE:BCEI), Arotech Corporation (NASDAQ:ARTX)